In The News Posted July 3, 2019 Share Posted July 3, 2019 SILVER SPRING, Md., July 3, 2019 /PRNewswire/ -- Today, the U.S. Food and Drug Administration granted accelerated approval to Xpovio (selinexor) tablets in combination with the corticosteroid dexamethasone for the treatment of adult patients with relapsed refractory multiple myeloma... View the full article Link to comment Share on other sites More sharing options...
Recommended Posts
Archived
This topic is now archived and is closed to further replies.